S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products. Its product pipeline comprises TED-N, which is in phase 1/2a clinical development for the treatment of subacute spinal cord injury; TED-A9, which is in phase 1/2a clinical development for the treatment of parkinson’s disease; FECS-Ad, which is 1/2a for the treatment of critical limb ischemia; FECS-DF, which is in phase 1/2 clinical development for the treatment of crows feet; TED-R for the treatment of macular degeneration; CF-TED-N for the treatment of stroke; and CF-FECS-DF for the treatment of wound. The company provides testing services; and owns platform technologies for developing cell therapy products. S.Biomedics CO., LTD. was founded in 2005 and is headquartered in Seoul, South Korea.
Metrics to compare | 304360 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship304360PeersSector | |
---|---|---|---|---|
P/E Ratio | −36.2x | −7.7x | −0.5x | |
PEG Ratio | −0.94 | 0.02 | 0.00 | |
Price/Book | 20.4x | 2.5x | 2.6x | |
Price / LTM Sales | 17.6x | 14.4x | 2.9x | |
Upside (Analyst Target) | - | 0.0% | 49.4% | |
Fair Value Upside | Unlock | 13.9% | 8.2% | Unlock |